Latest filing published 21 May 2026 for ClearPoint Neuro, Inc., €49k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 9 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +38.4%Entry US$10.04 · Close at T+365 US$13.90
- +37.9%Entry US$4.64 · Close at T+365 US$6.40
- +87.1%Entry US$2.48 · Close at T+365 US$4.64
- +65.2%Entry US$2.76 · Close at T+365 US$4.56
- -82.3%Entry US$16.28 · Close at T+365 US$2.88
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Lynnette C. Fallon: trading record in brief
Lynnette C. Fallon (senior executive) discloses dealings in 2 companies, chiefly Axcelis Technologies Inc and ClearPoint Neuro, Inc. Between 30 December 2005 and 20 May 2026, the trades on record add up to 163 filings.
In open-market terms, that means 9 purchases worth €31k on one side and 60 sales worth €11.6M on the other. Sales outweigh purchases by €11.5M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 73 share grants and 17 option exercises. Since January 2026: no purchases and 1 sale on the market.
The median purchase comes to €1,401. After 9 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -13.8%. They describe history only and say nothing certain about the share price ahead.
The latest filing, published on 21 May 2026, reports an open-market sale of €49k in ClearPoint Neuro, Inc. The clock since the last published purchase (16 November 2015) now reads 4,010 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Lynnette C. Fallon
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,091 shares@ US$11.140.012% mcap33.0% of flowCommon StockSEC:0001193125-26-234575:1
- 12,417 sharesCommon StockSEC:0001193125-26-234575:0
- 1,200 shares@ US$12.888.4% of flowCommon StockSEC:0000950170-25-082344:1
- 9,000 shares@ US$12.5367.0% of flowCommon StockSEC:0000950170-25-082344:0
- 21,093 sharesCommon StockSEC:0000950170-25-074501:0
- 3,083 shares@ US$71.965.0% of flowCommon StockSEC:0001415889-25-000958:0
- 272 shares@ US$111.290.6% of flowCommon StockSEC:0001415889-24-015556:0
- 872 shares@ US$113.232.1% of flowCommon StockSEC:0001415889-24-013739:0
- 1,017 shares@ US$112.940.8% of flowCommon StockSEC:0001415889-24-013487:1
- 300 shares@ US$112.940.2% of flowCommon StockSEC:0001415889-24-013487:2
- 628 shares@ US$113.570.5% of flowCommon StockSEC:0001415889-24-013487:3
- 3,200 shares0Common StockSEC:0001415889-24-013487:0
- 17,153 sharesCommon StockSEC:0001285550-24-000059:0
- 536 sharesCommon StockSEC:0001415889-24-006103:1
- 1,123 sharesCommon StockSEC:0001415889-24-006103:0
- 365 shares0Common StockSEC:0001209191-23-058768:0
- 3,098 shares@ US$181.3212.1% of flowCommon StockSEC:0001209191-23-048637:0
- 1,584 shares@ US$172.735.9% of flowCommon StockSEC:0001209191-23-035069:0
- 1,881 shares@ US$152.206.2% of flowCommon StockSEC:0001209191-23-032147:0
- 872 shares@ US$137.690.9% of flowCommon StockSEC:0001209191-23-030583:1
- 2,410 shares@ US$141.552.5% of flowCommon StockSEC:0001209191-23-030583:2
- 628 shares@ US$129.921.7% of flowCommon StockSEC:0001209191-23-030583:0
- 1,263 shares@ US$127.993.4% of flowCommon StockSEC:0001209191-23-029944:2
- 1,209 shares@ US$127.993.3% of flowCommon StockSEC:0001209191-23-029944:3
- 4,120 shares@ US$129.8411.4% of flowCommon StockSEC:0001209191-23-029944:4
25 of 157 declarations
